Quantum Biopharma (QNTM) Cash from Financing Activities (2019 - 2026)

Quantum Biopharma has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $7.0 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $7.0 million, up 123.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 million (down 29.75% YoY), and the FY2025 annual result was $6.1 million, down 47.51% from the prior year.
• Cash from Financing Activities came in at $7.0 million for Q1 2026 at Quantum Biopharma, up from $1.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.0 million in Q1 2026 to a low of -$4.1 million in Q4 2022.
• The 4-year median for Cash from Financing Activities is $1.4 million (2025), against an average of $1.7 million.
• Peak annual rise in Cash from Financing Activities reached 450.97% in 2025, while the deepest fall reached 96.12% in 2025.
• Quantum Biopharma's Cash from Financing Activities stood at -$4.1 million in 2022, then soared by 160.34% to $2.5 million in 2024, then plunged by 42.68% to $1.4 million in 2025, then surged by 394.82% to $7.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.0 million (Q1 2026), $1.4 million (Q4 2025), and $261425.0 (Q3 2025), per Business Quant data.